Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home
Share
Compartir

Fact Sheet

CLINICAL FEATURES

  • Sudden onset of fever, severe headache, myalgias and arthralgias, leukopenia, thrombocytopenia and hemorrhagic manifestations
  • Occasionally produces shock and hemorrhage, leading to death

ETIOLOGIC AGENT

  • Dengue viruses (DENV 1, DENV 2, DENV 3, and DENV 4) - flaviviruses

INCIDENCE

  • Variable, depending on epidemic activity.
  • Globally, there are an estimated 50 to 100 million cases of dengue fever (DF) and several hundred thousand cases of dengue hemorrhagic fever (DHF) per year
  • Case fatality rate can be as high as 10%. Can be reduced to as low as 1% with early recognition and proper treatment.
  • In 2007, 900,782 cases of DF and 26,413 cases of DHF reported in Americas. Outbreaks were reported in 11 countries.
  • Between 100 to 200 suspected cases introduced into U.S. each year by travelers

SEQUELAE

  • None

COSTS

  • $250 million estimated in Puerto Rico in past 10 years

TRANSMISSION

  • Mosquito-borne (Aedes Aegypti)

RISK GROUPS

  • Residents of or visitors to tropical and subtropical environments, especially urban and suburban areas
  • Increased severe and fatal disease in children under 15 years
  • No cross-immunity from each serotype
  • A person can potentially experience four dengue infections

SURVEILLANCE

  • DF and DHF are designated as reportable disease by law in US
  • Dengue Branch responsible for laboratory-based surveillance
  • Laboratory-based surveillance in endemic areas outside of US and it territories  

TRENDS

  • Resurgent disease in tropical and subtropical areas worldwide 
  • Epidemics have increased in size and frequency
  • Transmission in continental U.S. last reported in 2005 first since 1986
  • Since first epidemic in 1981, DHF now reported from 18 countries in the Americas
  • Evolution of disease pattern in Americas similar to SE Asia in 1950s and 1960s

CHALLENGES

  • Increased incidence associated with increased urbanization
  • More rapid dispersal of viruses via increased air travel
  • Vector control methods used to respond to an epidemics have not  shown evidence of effectiveness
  • Severe hemorrhagic disease poorly understood by physicians
  • Need to increase effective epidemic prevention methods
  • Need to increase community participation in prevention and control programs

RESEARCH OPPORTUNITIES and PRIORITIES

  • Develop improved laboratory-based international surveillance
  • Develop rapid, sensitive and specific diagnostic tests
  • Develop more effective community-based prevention programs
  • Develop tetravalent dengue vaccine
  • Dengue Branch, designated WHO Reference Center
  • Increased  medical community education
 
Contact Us:
  • Centers for Disease Control and Prevention
    Dengue Branch
    1324 Calle Cañada
    San Juan, Puerto Rico
    00920-3860
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #